Are We Going to See a Decline in Construction Revenues?

Due to both the higher interest rates on their own and the reduced spending that will be caused by the recession, non-residential construction will decline in the next year or so. Armstead Jones, President, Imagine Think Tank gives his perspective on why property owners are going to see a decline in construction revenues over the next 12 months:

“We’re going to see a decline in construction revenues over the next 12 months because of a bunch of key indicators. Number one, interest rates, and number two, inflation. Those things are going to cause permits to slow down, so when construction companies go to do work, on job sites, they’ll pull permits in order to start certain phases of work.

Owners, developers, property owners, and landowners are slowing down because interest rates have wrecked their performers and their models, and inflation has jacked up their costs. So with all of these things happening, they’re slowing down on the completion of projects, which slows down the construction industry, which then slows down subs in that construction industry as well.”

Follow us on social media for the latest updates in B2B!

Image

Latest

vitro
Analyzing the Suppressive TME in In Vitro Based Assays
April 19, 2025

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

Read More
cancer
Targeting T Cells Within the Cancer Immunity Cycle
April 19, 2025

As cancer immunotherapy continues to reshape treatment landscapes, fine-tuning T-cell responses has become a critical frontier. Recent advances in 3D organoid models and high-content imaging are enabling scientists to closely mimic patient-specific tumor environments—unlocking insights into how T cells behave, respond, and falter under immune checkpoint blockade. With over 4,000 immune modulators in clinical…

Read More
cancer Immunity cycle
Advanced In Vitro Technologies to Investigate Therapeutic Impact on the Cancer Immunity Cycle
April 19, 2025

As immunotherapy revolutionizes cancer treatment, the need for physiologically relevant preclinical models becomes more urgent than ever. Despite the success of immune checkpoint inhibitors, a large majority of patients fail to achieve long-lasting responses, prompting researchers to explore more complex and predictive assays. The cancer immunity cycle, first described in 2013, remains a central framework…

Read More
resistance
Inside Oncology Drug Development: Overcoming Resistance with Science
April 19, 2025

In the last two decades, oncology has undergone a transformation with over 300 new cancer therapies approved by the FDA—many offering novel mechanisms of action. Despite these innovations, resistance to treatment remains a critical challenge, with cancer cells evolving or adapting to evade even the most advanced therapeutics. This issue is particularly pressing given that…

Read More